Health Prob Civil. 2025; 19(4): 361-369.
1. Czajka H. [Why are preventive vaccinations still required?]. Med Okr Rozw. 2018; XXII(2): 171-179 (in Polish).
2.
Lusawa A, Pinkas J, Zgliczyński WS, Mazurek M, Wierzba W. [False information by vaccination movements as a challenge for public health]. Zdr Publiczne i Zarządzanie. 2019; 17(1): 40-45 (in Polish). https://doi.org/10.4467/20842627OZ.19.006.11302
3.
Krzyżanowski, F. [Use of whole-cell pertussis vaccine in the implementation of the Protective Vaccination Program]. Lekarz POZ. 2024; 10(4): 297-302 (in Polish).
4.
Państwowy Zakład Higieny. [Historical protective vaccination programs] [Internet]. Warszawa: Państwowy Zakład Higieny [access 2025 Aug 4]. Available from: https://szczepienia.pzh.gov.pl/kalendarz-szczepien/ (in Polish).
5.
[Announcement by the Chief Sanitary Inspector of October 31, 2024, regarding the Protective Vaccination Program for 2025] (in Polish).
6.
Główny Urząd Statystyczny. [Percentage of vaccinated children and adolescents in a given age group who have immunization cards] [Internet]. Warszawa: GUS; 2024 [access 2024 Aug 20]. Available from: https://dbw.stat.gov.pl/baza-danych (in Polish).
7.
Państwowy Zakład Higieny. [Number of whooping cough cases in 2019-2020] [Internet]. Warszawa: Państwowy Zakład Higieny; 2020 [access 2024 Aug 20]. Available from: https://szczepienia.pzh.gov.pl/wp-content/uploads/2020/02/Post_krztusiec.png (in Polish).
8.
Państwowy Zakład Higieny. [Measles in Poland – data for 01.01.2005-31.12.2021] [Internet]. Warszawa: Państwowy Zakład Higieny; 2020 [access 2024 Aug 20]. Available from: https://szczepienia.pzh.gov.pl/wp-content/uploads/2022/12/ODRA-do-2021.pdf (in Polish).
9.
World Health Organization. Measles reported cases and incidence [Internet]. Geneva: WHO; 2024 [access 2024 Aug 20]. Available from: https://immunizationdata.who.int/global/wiise-detail-page/measles-reported-cases-and-incidence?CODE=EUR+POL&YEAR=
10.
World Health Organization. Pertussis reported cases and incidence [Internet]. Geneva: WHO; 2024 [access 2024 Aug 20]. Available from: https://immunizationdata.who.int/global/wiise-detail-page/pertussis-reported-cases-and-incidence?CODE=EUR+POL&YEAR=
11.
Holka J, Pawlak K, Ciepiela O. Seroprevalence of IgG antibodies against measles in a selected Polish population – Do we need to be re-vaccinated?. Cent Eur J Immunol. 2019; 44(4): 380-383. https://doi.org/10.5114/ceji.2019.92789
12.
[Joint recommendations of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the Latin America Confederation of Clinical Biochemistry (COLABIOCLI) on venous blood collection recommended by the National Chamber of Laboratory Diagnosticians and the Polish Society of Laboratory Diagnostics] [Internet]. Warszawa: Medical University of Warsaw; 2018 [access 2024 May 20]. Available from: https://zdl.wum.edu.pl/sites/zdl.wum.edu.pl/files/rekomendacje_dotyczace_pobierania_krwi_zylnej-2.pdf (in Polish).
13.
Chen Z, He Q. Immune persistence after pertussis vaccination. Hum Vaccin Immunother. 2017; 13(4): 744-756. https://doi.org/10.1080/21645515.2016.1259780
14.
Bianchi FP, Mascipinto S, Stefanizzi P, De Nitto S, Germinario C, Tafuri S. Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study. Hum Vaccines Immunother. 2021; 17(7): 2078-2084. https://doi.org/10.1080/21645515.2020.1871296
15.
Orsi A, Butera F, Piazza MF, Schenone S, Canepa P, Caligiuri P, et al. Analysis of a 3-months measles outbreak in western Liguria, Italy: Are hospital safe and healthcare workers reliable?. J Infect Public Health. 2020; 13(4): 619-624. https://doi.org/10.1016/j.jiph.2019.08.016
16.
European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU/EEA (ESACNet) [Internet]. Stockholm: European Centre for Disease Prevention and Control; 2023 [access 2024 Sep 2]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobialconsumption-ESAC-Net-annual-epidemiological-report-2023_0.pdf
17.
Yalcın BNB, Sasmaz CT. Measles seroprevalence and related factors in women aged 15-49 years old, in Mersin, Turkey. Iran J Public Health. 2023; 52(3): 593-602.
18.
Państwowy Zakład Higieny. [How was the measles vaccine used in the past?] [Internet]. Warszawa: Państwowy Zakład Higieny; 2020 [access 2024 Aug 14]. Available from: https://szczepienia.pzh.gov.pl/faq/jak-szczepionka-przeciw-odrze-byla-stosowana-w-przeszlosci/ (in Polish).
19.
Kennedy RB, Ovsyannikova IG, Thomas A, Larrabee BR, Rubin S PG. Differential durability of immune responses to measles and mumps following MMR vaccination. Vaccine. 2019; 37(13): 1775-1784. https://doi.org/10.1016/j.vaccine.2019.02.030
20.
Anichini G, Gandolfo C, Fabrizi S, Miceli GB, Terrosi C, Savellini GG, et al. Seroprevalence to measles virus after vaccination or natural infection in an adult population, in Italy. Vaccines. 2020; 8(1): 66. https://doi.org/10.3390/vaccines8010066
21.
European Centre for Disease Prevention and Control. Pertussis [Internet]. Stockholm: European Centre for Disease Prevention and Control; 2019 [access 2024 Sep 2]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_pertussis.pdf
22.
Grassi T, Bagordo F, Savio M, Rota MC, Vitale F, Arghittu A, et al. Sero-epidemiological study of Bordetella pertussis infection in the Italian general population. Vaccines. 2022; 10(12): 1-11. https://doi.org/10.3390/vaccines10122130
23.
Esteghamati A, Sayyahfar S, Alimohamadi Y, Salahi S, Faramarzi M. Is it time to administer acellular pertussis vaccine to childbearing age/pregnant women in all areas using whole-cell pertussis vaccination schedule?. Ther Adv Vaccines Immunother. 2021; 9: 1-8. https://doi.org/10.1177/25151355211015842
Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
